<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262730</url>
  </required_header>
  <id_info>
    <org_study_id>NABTT-0501 CDR0000454915</org_study_id>
    <secondary_id>U01CA062475</secondary_id>
    <secondary_id>NABTT-0501</secondary_id>
    <nct_id>NCT00262730</nct_id>
  </id_info>
  <brief_title>Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
  <official_title>A Phase II Trial of Radiation Plus Temozolomide Followed by Adjuvant Temozolomide and Poly-ICLC in Patients With Newly Diagnosed Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in
      chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells,
      either by killing the cells or by stopping them from dividing. Biological therapies, such as
      poly ICLC, may stimulate the immune system in different ways and stop tumor cells from
      growing. Giving poly ICLC after radiation therapy and temozolomide may stop any remaining
      tumor cells from growing.

      PURPOSE: This phase II trial is studying how well giving radiation therapy together with
      temozolomide followed by temozolomide and poly ICLC works in treating patients with newly
      diagnosed glioblastoma multiforme.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the safety and efficacy of radiation plus low-dose temozolomide followed by
           adjuvant temozolomide and intramuscular poly ICLC for adult patients with newly
           diagnosed glioblastoma multiforme.

      Secondary

        -  Estimate the frequency of toxicity associated with this treatment regimen.

      OUTLINE: This is an open-label, multicenter study.

        -  Induction chemoradiotherapy: Patients undergo radiotherapy once daily, 5 days a week,
           for 6 weeks. During the same 6 weeks, patients also receive oral temozolomide once
           daily. Four weeks later, patients are evaluated for disease progression. Patients with
           progressive disease are removed from the study. Patients with no progressive disease
           proceed to maintenance therapy.

        -  Maintenance therapy: Patients receive oral temozolomide once daily on days 1-5 (week 1).
           Patients also receive poly ICLC intramuscularly three times a week in weeks 2-8. Courses
           repeat every 9 weeks in the absence of disease progression or unacceptable toxicity.

      After completion of study therapy, patients are followed every 2 months for survival.

      PROJECTED ACCRUAL: A total of 96 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>30 months</time_frame>
    <description>survival time is defined from time of histological diagnosis to death occurrence.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RT + TMZ 6wks, followed by
poly ICLC, temozolomide, radiation: radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>poly ICLC</intervention_name>
    <description>20 mcg/kg 3x each week (Maintenance cycles)</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Holtonol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant)</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Temodar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>RT: 60 Gy (6 weeks) concomitant therapy</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>RT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed supratentorial grade IV astrocytoma (glioblastoma multiforme)
             by biopsy or resection within the past 3 months

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status ≥ 60%

          -  Absolute neutrophil count ≥ 1500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Bilirubin ≤ 1.5 mg/dL

          -  Transaminases ≤ 4 times above the upper limits of the institutional normal

          -  Creatinine ≤ 1.7 mg/dL

          -  Not pregnant or breast-feeding

          -  Patients must agree to follow acceptable birth control methods to avoid conception

          -  Negative pregnancy test

          -  Patients must have a Mini Mental State Exam score of ≥ 15

          -  No serious concurrent infection or medical illness which would jeopardize the ability
             of the patient to receive the treatment outlined in this protocol with reasonable
             safety

          -  Patients with a concurrent or prior malignancy are ineligible unless they are patients
             with curatively treated carcinoma-in-situ or basal cell carcinoma of the skin

               -  Patients who have been free of disease (any prior malignancy) for ≥ five years
                  are eligible for this study

          -  Patients requiring ongoing therapy for psychoses with antipsychotic medications at the
             time of enrollment will be ineligible

        PRIOR CONCURRENT THERAPY:

          -  Patients must not have received prior radiation therapy, chemotherapy, immunotherapy
             or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense,
             peptide receptor antagonists, interferons, interleukins, TIL, LAK or gene therapy), or
             hormonal therapy for their brain tumor

               -  Prior glucocorticoid therapy is allowed

          -  Patients must be willing to forego other cytotoxic and non-cytotoxic drug therapy
             against the tumor while being treated with poly ICLC plus temozolomide on this
             protocol

          -  No other concurrent therapy for their tumor (i.e., chemotherapeutics or
             investigational agents)

          -  Patients who have received prior Gliadel wafers are not eligible for this study

          -  No concurrent prophylactic filgrastim (G-CSF)

          -  No concurrent electron, particle, implant, or stereotactic radiosurgery boost
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myrna Rosenfeld, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute at University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center at Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rosenfeld MR, Chamberlain MC, Grossman SA, Peereboom DM, Lesser GJ, Batchelor TT, Desideri S, Salazar AM, Ye X. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol. 2010 Oct;12(10):1071-7. doi: 10.1093/neuonc/noq071. Epub 2010 Jul 8.</citation>
    <PMID>20615924</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2005</study_first_submitted>
  <study_first_submitted_qc>December 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2005</study_first_posted>
  <results_first_submitted>March 22, 2013</results_first_submitted>
  <results_first_submitted_qc>June 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2014</results_first_posted>
  <last_update_submitted>June 16, 2014</last_update_submitted>
  <last_update_submitted_qc>June 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Poly ICLC</mesh_term>
    <mesh_term>Poly I-C</mesh_term>
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>outpatient clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Arm - All Subjects</title>
          <description>poly ICLC, temozolomide, radiation: radiation therapy
poly ICLC : 20 mcg/kg 3x each week (Maintenance cycles)
temozolomide : daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant)
radiation therapy : RT: 60 Gy (6 weeks) concomitant therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm - All Subjects</title>
          <description>poly ICLC, temozolomide, radiation: radiation therapy
poly ICLC : 20 mcg/kg 3x each week (Maintenance cycles)
temozolomide : daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant)
radiation therapy : RT: 60 Gy (6 weeks) concomitant therapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="97"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.6" lower_limit="21" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Status</title>
          <description>100 normal no complaints no disease 90 capable of normal activity few symptoms/disease 80 normal activity with some difficulty some symptoms or signs 70 caring for self not capable of normal activity or work 60 requiring some help can take care of most personal requirements 50 requires help often requires frequent medical care 40 disabled requires special care and help 30 severely disabled hospital admission indicated but no risk of death 20 very ill urgently requiring admission requires supportive measures or treatment 10 moribund rapidly progressive fatal disease processes 0 death</description>
          <units>Units on a scale</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Extent of surgery</title>
          <units>Patient</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Biopsy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craniotomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>time from diagnosis to radiotherapy</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.4" lower_limit="2" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Mini-Mental State Examiniation (MMSE) Score</title>
          <description>The mini–mental state examination (MMSE) is a 30-point questionnaire test used to screen for cognitive impairment. Commonly used to screen for dementia. It is also used to estimate the severity of cognitive impairment and to follow the course of cognitive changes in an individual over time. The MMSE test includes simple questions and problems in a number of areas: the time and place of the test, repeating lists of words, arithmetic such as the serial sevens, language use and comprehension, and basic motor skills. The Higher your score, the higher your function.</description>
          <units>Scores on a Scale</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>27-29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Less than or equal 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Corticosteroid Therapy</title>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histologic Diagnosis</title>
          <units>Patient</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Glioblastoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anaplastic Astrocytoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival</title>
        <description>survival time is defined from time of histological diagnosis to death occurrence.</description>
        <time_frame>30 months</time_frame>
        <population>all patients who were treated were analyzed (intent to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm - All Subjects</title>
            <description>poly ICLC, temozolomide, radiation: radiation therapy
poly ICLC : 20 mcg/kg 3x each week (Maintenance cycles)
temozolomide : daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant)
radiation therapy : RT: 60 Gy (6 weeks) concomitant therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>survival time is defined from time of histological diagnosis to death occurrence.</description>
          <population>all patients who were treated were analyzed (intent to treat)</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" lower_limit="15.4" upper_limit="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>study design has 85% power to detect 25% deduction in hazard rate compared to EORTC Phase 3 results.</non_inferiority_desc>
            <p_value>&gt;.1</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.8</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>While on Treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Arm All Subjects</title>
          <description>poly ICLC, TMZ, RT: poly ICLC : 20 mcg/kg 3x each week (Maintenance cycles) TMX : daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant) RT : RT: 60 Gy (6 weeks) concomitant therapy
AEs Grades 4 with Attributions of Possible, probably or definitely related to TMZ AND poly-ICLI</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>platelets</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>SGOT</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>&quot;Other Adverse Events&quot; not reported for this study. Only serious(grade 3/4)related to either TMZ and/or Poly were reported. Subjects may have experienced grade 1 and grade 2 other adverse event but they have no bearing on clinical outcome of agent</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director of Adult Brain Tumor Consortium</name_or_title>
      <organization>Adult Brain Tumor Consortium Central Office- Johns Hopkins</organization>
      <phone>410-955-3657</phone>
      <email>jfisher@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

